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ameliorating effect on colitis.  Conclusion: The data of this 
study indicate that in addition to intraperitoneal application, 
intrarectal delivery of cannabinoids may represent a useful 
therapeutic administration route for the treatment of colon-
ic inflammation.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Inflammatory bowel diseases (IBD) affect more than 
3 million people in the western world  [1] . Advances in the 
therapy of IBD have been achieved with new immuno-
suppressive and immunomodulatory agents; however, 
current pharmacological treatment still relies on nonste-
roidal and steroidal anti-inflammatory drugs, treatments 
that may cause severe side effects  [2] . With the advent of 
the so-called novel biologicals (e.g. tumor necrosis factor 
  antibodies), new hope was sparked for a more effective 
treatment of IBD, yet severe side effects and tolerance as-
sociated with long-term use of these drugs have damp-
ened these outlooks  [3] . Although currently used medica-
tion can keep IBD patients in relatively long states of re-
mission, a more effective cure with fewer side effects is a 
desirable aim. Cannabinoids have recently moved into 
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 Abstract 
 Background/Aims: Compounds of  Cannabis sativa are 
known to exert anti-inflammatory properties, some of them 
without inducing psychotropic side effects. Cannabidiol 
(CBD) is such a side effect-free phytocannabinoid that im-
proves chemically induced colitis in rodents when given in-
traperitoneally. Here, we tested the possibility whether rec-
tal and oral application of CBD would also ameliorate colon-
ic inflammation, as these routes of application may represent 
a more appropriate way for delivering drugs in human colitis. 
 Methods: Colitis was induced in CD1 mice by trinitroben-
zene sulfonic acid. Individual groups were either treated 
with CBD intraperitoneally (10 mg/kg), orally (20 mg/kg) or 
intrarectally (20 mg/kg). Colitis was evaluated by macroscop-
ic scoring, histopathology and the myeloperoxidase (MPO) 
assay.  Results: Intraperitoneal treatment of mice with CBD 
led to improvement of colonic inflammation. Intrarectal 
treatment with CBD also led to a significant improvement of 
disease parameters and to a decrease in MPO activity while 
oral treatment, using the same dose as per rectum, had no 
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the center of inflammation research. But despite the fact 
that  Cannabis sativa has traditionally been used for cen-
turies as an analgesic and anti-inflammatory remedy, 
modern pharmacological therapy of inflammation with 
cannabinoids is still at the beginning. A recent article has 
highlighted that between 33 and 50% of people suffering 
from IBD have been using  Cannabis to relieve IBD-relat-
ed symptoms  [4] . In line with this, animal models of IBD 
largely suggest that cannabinoid compounds and activa-
tion of cannabinoid (CB) receptors significantly suppress 
the severity of colitis  [5–7] . In addition, non-CB receptor-
mediated effects of cannabinoids can also cause improve-
ment of experimental colitis  [8, 9] .
 A major obstacle for the pharmacological exploitation 
of cannabinoids lies in their psychotropic side effects. This 
applies particularly to cannabinoids with strong cannabi-
noid 1 receptor (CB1) activity, such as   9 -tetrahydrocan-
nabinol (THC)  [10] but also for CB1 antagonists, such as 
rimonabant  [11] . However, some cannabinoids, e.g. can-
nabidiol (CBD) and O-1602, are known to be anti-inflam-
matory  [9, 12, 13] while being free of adverse central side 
effects  [12, 14] . CBD has already proven effective in de-
creasing the severity of experimental colitis in rodents  [8] . 
Due to its low activity at CB receptors  [15, 16] and its lack 
of psychoactivity  [17, 18] , CBD could become an impor-
tant candidate for the treatment of IBD. Since orally taken 
cannabinoids are prone to significant metabolization in 
the liver  [19] , the route of application for cannabinoids is 
of major importance. For instance, Sativex  , a 1: 1 mixture 
of THC and CBD (GW Pharma, Salisbury, UK), is given 
as an oromucosal spray to avoid first-pass metabolism by 
the liver and degradation in the intestine  [20] .
 To address the question of the appropriate route for the 
application of cannabinoids in IBD treatment, we used an 
established mouse model of colitis (trinitrobenzene sul-
fonic acid [TNBS] model) and applied CBD systemically, 
orally and per rectum, to prevent the severity of colitis. 
We found that CBD not only protected from colitis when 
given systemically, but was also effective when given lo-
cally per rectum. Oral application of CBD, used at the 
same dose as per rectum, was not effective in protecting 
from colitis in this mouse model.
 Materials and Methods 
 CD1 mice (males, 5–9 weeks old, 24–35 g) were purchased 
from Charles River (Deisenhofen, Germany) and kept in house at 
least for 2 weeks prior to experiments. Mice were housed in plas-
tic sawdust floor cages at a constant temperature (22   °   C) and a 
12-hour:12-hour light-dark cycle with free access to standard lab-
oratory chow and tap water. Experimental procedures were ap-
proved by the ethics committee of the Austrian Federal Ministry 
of Science and Research (BMWF-66.010/0109-II/3b/2010) and 
carried out in line with the European Communities Council Di-
rective.
 Induction of TNBS Colitis 
 Animals were lightly anesthetized with isoflurane. TNBS
(4 mg in 100   l of 30% ethanol) was then infused into the colon 
through a catheter (outside diameter 1 mm) inserted 3 cm proxi-
mally to the anus. Solvent alone (100   l of 30% ethanol) was ad-
ministered in control experiments. The dose of TNBS was previ-
ously found to induce reproducible colitis with mortality rates in 
the published range  [6] .
 Drugs and Pharmacological Treatments 
 TNBS was purchased from Sigma-Aldrich (Vienna, Austria) 
and CBD was provided by GW Pharma. CBD treatment was start-
ed 1 day before TNBS induction and given once daily until the end 
of the experiments (3 days after TNBS induction). For intraperi-
toneal treatment (10 mg/kg), CBD was dissolved in vehicle (etha-
nol, Tween 20 and sterile saline at 1: 1:8). For intragastric (by ga-
vage) and intrarectal (by use of a catheter) treatments, canola oil 
was used as a vehicle. Experiments were also performed with the 
respective vehicles.
 Macroscopic Scoring and Damage Assessment 
 At the end of the TNBS colitis experiments, mice were killed 
by cervical dislocation. The colon was immediately removed, 
rinsed gently with saline solution, opened longitudinally along 
the mesenteric border and examined. Colonic damage was as-
sessed by a semiquantitative scoring system adapted for mice in 
the present study  [6] . Macroscopic damage was scored according 
to the following scale, adding individual scores for ulcer, adhe-
sion, colonic shortening, wall thickness, and presence of hemor-
rhage, fecal blood or diarrhea. Ulcer: 0.5 points for each 0.5 cm; 
adhesion: 0 points = absent, 1 point = 1 adhesion, 2 points = 2 or 
more adhesions or adhesions to organs; shortening of the colon: 
1 point =  1 15%, 2 points =  1 25% (based on a mean length of the 
untreated colon); wall thickness measured in millimeters. The 
presence of hemorrhage, fecal blood or diarrhea increased the 
score by 1 point for each additional feature.
 Histology 
 Following macroscopic scoring, segments of the distal colon 
were stapled flat onto cardboard with the mucosal side up and 
fixed for 24 h in 10% neutral-buffered formalin. Tissue was then 
dehydrated, embedded in paraffin and standard hematoxylin/eo-
sin staining was performed on 5-  m-thick sections.
 Determination of Tissue Myeloperoxidase Activity 
 Myeloperoxidase (MPO) activity represents an index of neu-
trophil accumulation in the tissue and correlates with the severity 
of the colitis  [21] . Samples of colon were weighed, immediately 
frozen, and stored at –80   °   C prior to further processing. For the 
determination of MPO activity, tissue was placed in 0.5% hexa-
decyltrimethylammonium bromide buffer (50 mg of tissue/ml; pH 
6.0) and disrupted with a homogenizer (UltraTurrax  , IKA, Ger-
many). Hexadecyltrimethylammonium bromide (Sigma-Aldrich) 
is a detergent that releases MPO from the primary granules of neu-
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trophils and enhances enzyme activity by the presence of bromide. 
Afterwards, the homogenate was centrifuged for 15 min at maxi-
mum speed and 4  °  C. Before reading MPO activity, 7   l of super-
natant was added to 200   l of 50 mmol/l potassium phosphate 
buffer (pH 6.0) containing 0.167 mg/ml of O-dianisidine hydro-
chloride and 0.5   l of 1% H 2 O 2 /ml. The kinetics of MPO activity 
was measured at 460 nm (xMark TM , Bio-Rad, Austria). A mean 
was calculated for the respective TNBS + vehicle-treated groups 
and set at 100%. Values of the CBD treatment groups are expressed 
as percent of the respective TNBS + vehicle-treated group.
 Statistical Analysis 
 From every experimental group, a mean was calculated and 
differences of means between groups were analyzed by one-way 
ANOVA followed by Tukey’s post hoc test using Graph Pad Prism 
(Graph Pad Software, San Diego, Calif., USA). p values  ! 0.05 were 
considered significant.
 Results 
 In all treatment groups, mice lost around 10–15% of 
their body weights after induction of TNBS colitis; how-
ever, no differences were observed in body weights
between CBD-treated (intraperitoneal, intragastric
and intrarectal) and the respective vehicle-treated mice 
( fig. 1 ).
 In accordance with Borrelli et al.  [8] , intraperitoneal 
injection of 10 mg/kg CBD (once daily) caused a signifi-
cant improvement of the colitis score index and a de-
crease in MPO activity ( fig. 2 ). In mice treated with in-
traperitoneal CBD, histological sections from lesioned 
areas revealed less destruction of the epithelial lining, a 
reduction in colon thickness and less infiltration of im-
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 Fig. 1. Graphs showing weight changes (%) in mice during TNBS 
colitis. No significant differences were seen between vehicle-
treated TNBS mice and TNBS mice that received CBD intraperi-
toneally ( a ), intragastrically ( b ) or intrarectally ( c ). Treatment 
with CBD (or with the respective vehicle) was started 1 day before 
application of TNBS and continued once daily for 3 more days. 
Until the end of the experiment, mice lost about 15% of their body 
weight. n = 8; significances were tested by one-way ANOVA and 
Tukey’s post hoc test. 
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munocytes, as compared to intraperitoneally vehicle-
treated mice ( fig. 3 ). Intragastric treatment with CBD (20 
mg/kg; once daily) did not lead to an improvement of the 
colitis score ( fig. 2 ). The 20 mg/kg dose for the intragas-
tric treatment was chosen because it proved effective in 
an inflammatory and neuropathic pain model of the rat 
 [22] . By applying the same dose for intrarectal treatment 
(20 mg/kg; once daily), a small but significant improve-
ment of the colitis score index was observed ( fig. 2 ). MPO 
activity was significantly decreased indicating a reduc-
tion in the severity of the inflammation ( fig. 2 ). A repre-
sentative histological section from a lesioned area in the 
colon of intrarectally CBD-treated mice shows reduced 
leukocyte infiltration and partially preserved crypt ar-
chitecture in comparison to intrarectally vehicle-treated 
mice ( fig. 3 ).
 Discussion 
 Over the last decade, cannabinoids and the endocan-
nabinoid system (ECS) have become a hot topic in inflam-
mation research, and evidence is multifold that cannabi-
noids can protect against different forms of inflammation 
by targeting CB receptors and other structures within the 
ECS. Regarding the gastrointestinal tract, cannabinoid-
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 Fig. 2. Macroscopic scoring and MPO activity assays of mice with 
TNBS colitis. Intraperitoneal injection of 10 mg/kg CBD (once 
daily) caused a significant improvement of the colitis score index 
( a ; n = 11–13) and a decrease in MPO activity ( b ; n = 9–10). Intra-
rectal application of 20 mg/kg CBD also significantly improved 
colitis parameters ( e ; n = 11) and decreased MPO activity ( f ; n = 
11).  c Intragastric treatment with CBD (20 mg/kg) did not lead to 
improvement of the colitis score (n = 11–12).  d Differences in 
MPO activity were not significant (n = 8). Significances were test-
ed by one-way ANOVA and Tukey’s post hoc test. 
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induced protection against experimental gastrointestinal 
inflammation was first shown by Massa et al.  [5] in 2004 
and later confirmed and further characterized by others 
 [6, 8, 9, 23, 24] . We now know that these effects involve 
CB1 and CB2 receptors. Additional targeting of structures 
within the ECS, like the anandamide-degrading enzyme 
fatty acid amide hydrolase and the  endocannabinoid 
membrane transporter, results in protection against intes-
tinal inflammation  [25] . More importantly, translational 
studies indicate that the ECS is activated in human IBD 
 [26, 27] , suggesting that the ECS not only plays a crucial 
role in animal models of IBD, but also in human gastro-
intestinal inflammation. Concepts need to be developed 
therefore, as to how the knowledge generated from basic 
research can be translated into humans and how the dis-
covered mechanisms may be applied to result in future 
treatments of human IBD. Our present study confirms 
previously published studies  [8] for it shows that intra-
peritoneal CBD protects against intestinal inflammation 
and we can furthermore show that not only systemically, 
but also topically applied CBD is protective. This repre-
sents a significant extension of our knowledge on how to 
apply cannabinoids since previous studies in animal mod-
els of IBD focussed on pathophysiological mechanisms 
and, for the ease of use, cannabinoids were applied by in-
traperitoneal injections. Whereas this way of application 
is feasible in an experimental setup, there is little doubt 
that such a mode of action is unlikely to be translated into 
future therapeutic use for humans  [28] . The intraperito-
neal route has advantages over the oral route as it bypass-
es the hepatic metabolism of the employed cannabinoids. 
It is known that hepatic metabolization is a limiting factor 
of systemic cannabinoid use  [19] . Because promotion of 
inhaled (smoked) cannabinoids is not advisable from a 
health perspective, our study is of major interest as it 
shows for the first time that intrarectal application pro-
tects against intestinal inflammation. Intrarectal applica-
tion is an easy mode of drug application, especially for 
patients with distal colitis, rectosigmoiditis, proctitis and 
pouchitis. In human use, it is also one of the preferred 
modes of application for other compounds like steroids 
and aminosalicylates  [29] . Thus, our results promote the 
notion that a clinical investigation using CBD in patients 
with the above-mentioned diseases should be considered. 
Because CBD, as compared to other cannabinoids, has a 
favorable side effect profile  [18] , such a study seems fea-
sible. Hepatic first-pass effects were also demonstrated for 
cannabinoids of other composition, such as for THC  [19] , 
but in contrast to CBD, systemic (e.g. psychotropic) effects 
were still prevalent  [30] .
 In the present study, no effects of CBD were seen fol-
lowing oral application of 20 mg/kg, a dose that was 
shown to improve pain in rats caused by chronic sciatic 
nerve constriction and intraplantar injection of complete 
Freund’s adjuvant  [22] . Whether higher doses of CBD or 
 Fig. 3. The pictures depict representative histological sections of 
lesioned areas in the colon of TNBS mice. Moderate destruction of 
the epithelial lining and a reduction in leukocyte infiltration is 
seen in intraperitoneally (IP) CBD-treated mice, as compared to 
intraperitoneally vehicle-treated mice. An image of a lesioned area 
in the colon shows that the crypt architecture of the epithelium 
was more preserved in intrarectally (IR) CBD-treated mice than 
in intrarectally vehicle-treated mice. Calibration bar = 500   m. 
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nal inflammation may be a feasible option.
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